Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.6701 +0.0131 (+1.99%)
Streaming Delayed Price Updated: 11:41 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Reverse Stock Split
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
From PharmaCyte Biotech, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.